Get Fit Bharat

Tag: Interval

HomeInterval

Litton Das has been appointed as Bangladesh's captain for the upcoming three-match T20I series against the West Indies, marking the first time he will lead the side for an entire series. Litton previously stepped in as captain for a one-off match against New Zealand in April 2021. Several players like batting allrounder Shamim Hossain, who …

South Africa vs Pakistan 1st T20I, Live Score Updates© AFP South Africa vs Pakistan 1st T20I, Live Updates: South Africa will be squaring off against Pakistan in the first T20I of the three-match series on Tuesday in Durban. The hosts will be led by Heinrich Klaasen as the main team is currently facing …

Tel Aviv, Israel (December 10, 2024) – Eco Wave Power Global AB (publ) (Nasdaq: WAVE) (“Eco Wave Power” or the “Company”), a leading innovator in onshore wave energy technology, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 300,000 American Depositary Shares …

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO Stenocare has announced its STENOCARE 3.0 strategy, unveiled on November 26, which marks a bold new chapter in its mission to become a leader in the medical cannabis industry. This transformative strategy positions Stenocare as a specialised Trading Company, focused on delivering high-quality, …

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES TO DISTRIBUTE THIS ANNOUNCEMENT. EQL Pharma AB (publ) (the “Company” or “EQL”) today announces …

San Mateo, Calif., United States:   5-year follow-up from SEQUOIA study demonstrated treatment with BRUKINSA reduced the risk of progression or death by 71% compared to bendamustine-rituximab in patients with treatment-naïve CLL, further solidifying its position as the leader in new patient starts in both frontline and relapsed/refractory (R/R) CLL with …

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES TO DISTRIBUTE THIS ANNOUNCEMENT. EQL Pharma AB (publ) (the “Company” or “EQL”) today announces …